<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075681</url>
  </required_header>
  <id_info>
    <org_study_id>S-2020-483-01</org_study_id>
    <nct_id>NCT05075681</nct_id>
  </id_info>
  <brief_title>Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma</brief_title>
  <official_title>Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen for Patients With Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of Ruxolitinib and&#xD;
      Chidamide intensified conditioning regimen in patients with Acute T cell Lymphoblast&#xD;
      leukemia/ lymphoblastic lymphoma Underwenting Haploidenticl Peripheral blood Stem Cell&#xD;
      Transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haploidenticl Peripheral blood Stem Cell Transplantation should be offered to eligible&#xD;
      patients with Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma whenever feasible. To&#xD;
      further improve the outcome of transplantation patients with Acute T cell Lymphoblast&#xD;
      leukemia/ lymphoblastic lymphoma, we developed a modified Bu/Cy conditioning regimen&#xD;
      intensified by Ruxolitinib and Chidamide. In this study, we tested the efficacy and&#xD;
      feasibility of the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and&#xD;
      Chidamide in patients with Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma&#xD;
      undergoing allogeneic peripheral blood stem cell transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants relapse as assessed by NCCN (National Comprehensive Cancer Network ) criteria</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>Defined as the proportion of participants whose underlying malignancy relapsed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DFS(disease-free survival )</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>DFS was defined as survival with no evidence of relapse or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM(treatment-related mortality )</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>Defined as the proportion of subjects who died due to causes other than malignancy relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria)</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>Defined as the proportion of participants who developed acute GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with cGVHD as assessed by chronic graft versus host disease grading criteria (refer to NIH criteria)</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>Defined as the proportion of participants who developed chronic GVHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS(overall survival )</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>OS was defined as the time from transplantation to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>Defined as the time from transplantation to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection rate</measure>
    <time_frame>365 days after transplantation</time_frame>
    <description>Defined as the proportion of participants who developed all kinds of infection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Blood Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib combined with Chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide</intervention_name>
    <description>Drug: modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide.&#xD;
Day -15 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -14 # Ruxolitinib 70mg bid; Day -13 # Ruxolitinib 70mg bid; Day -12 # Ruxolitinib 70mg bid, Chidamide 30 mg once; Day -11 # Ruxolitinib 70mg bid; Day-10# Cytarabine 4g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9# Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 # Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid, Chidamide 30 mg once; Day- 7# Busulfan 0.8mg/ kg Q6h iv, Ruxolitinib 50mg bid; Day-6# Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5# Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid, Chidamide 30 mg once; Day-4# Cyclophosphamide 1.8 g/m2/day CI,Ruxolitinib 20mg bid; Day-3# Carmustine 250mg/m2/ day iv, Ruxolitinib 10mg bid; Day-2# Ruxolitinib 5mg bid, Chidamide 30 mg/day; Day-1# Ruxolitinib 5mg qd;</description>
    <arm_group_label>Ruxolitinib combined with Chidamide</arm_group_label>
    <other_name>Ruxolitinib and Chidamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. high risk Acute T cell Lymphoblast leukemia/ lymphoblastic lymphoma with the&#xD;
             indications for allogeneic transplantation;&#xD;
&#xD;
          2. Have haploidentical donors&#xD;
&#xD;
          3. All patients should aged 12 to 65 years;&#xD;
&#xD;
          4. Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times&#xD;
             the upper limit of normal;&#xD;
&#xD;
          5. Renal function: creatinine ≤the upper limit of normal;&#xD;
&#xD;
          6. Patients without any uncontrolled infections , without organ dysfunction or without&#xD;
             severe mental illness;&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;&#xD;
&#xD;
          8. Have signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnant women;&#xD;
&#xD;
          2. Patients with mental illness or other states unable to comply with the protocol;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daihong Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daihong Liu</last_name>
    <phone>86-13681171597</phone>
    <email>daihongrm@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liping Dou</last_name>
    <phone>96-13681207138</phone>
    <email>lipingruirui@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Cao</last_name>
      <phone>01066937166</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ferrante F, Giaimo BD, Bartkuhn M, Zimmermann T, Close V, Mertens D, Nist A, Stiewe T, Meier-Soelch J, Kracht M, Just S, Klöble P, Oswald F, Borggrefe T. HDAC3 functions as a positive regulator in Notch signal transduction. Nucleic Acids Res. 2020 Apr 17;48(7):3496-3512. doi: 10.1093/nar/gkaa088.</citation>
    <PMID>32107550</PMID>
  </reference>
  <reference>
    <citation>Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12;125(11):1759-67. doi: 10.1182/blood-2014-06-580480. Epub 2015 Feb 2.</citation>
    <PMID>25645356</PMID>
  </reference>
  <reference>
    <citation>Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017 Dec;31(12):2568-2576. doi: 10.1038/leu.2017.136. Epub 2017 May 9.</citation>
    <PMID>28484265</PMID>
  </reference>
  <reference>
    <citation>Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6.</citation>
    <PMID>28298231</PMID>
  </reference>
  <reference>
    <citation>Stumpel DJ, Schneider P, Seslija L, Osaki H, Williams O, Pieters R, Stam RW. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia. 2012 Apr;26(4):682-92. doi: 10.1038/leu.2011.278. Epub 2011 Oct 21.</citation>
    <PMID>22015773</PMID>
  </reference>
  <reference>
    <citation>Lato MW, Przysucha A, Grosman S, Zawitkowska J, Lejman M. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2021 Apr 26;22(9). pii: 4502. doi: 10.3390/ijms22094502. Review.</citation>
    <PMID>33925883</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Daihong Liu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

